Kornimate/medical-research-clean huggingface dataset:
elimination of ptv margins based on mri-guided adaptive stereotactic radiotherapy for non-small cell lung cancer with brain metastasis

Conditions: MRI-guided Adaptive Radiotherapy; Non-small Cell Lung Cancer; Brain Metastasis

Summary: this study aims to explore the safety and efficacy of eliminating the planning target volume (ptv) margins based on mri-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (nsclc) patients with brain metastasis.

this study aims to explore the safety and efficacy of eliminating the planning target volume (ptv) margins based on mri-guided adaptive stereotactic radiotherapy for nsclc patients with brain metastasis. in this study, patients will be randomly assigned in a 1:1 ratio to the study group or the control group. patients in the study group will receive mri-guided adaptive stereotactic radiotherapy (srt) (without ptv expansion margin), while patients in the control group will receive ct-guided conventional standard srt (with ptv expansion margin). after the completion of treatment, patients will be followed up regularly to assess safety and efficacy.

Eligibility criteria:
inclusion criteria: * aged 18-75 years * histologically or cytologically confirmed non-small cell lung cancer * 1-10 metastases on contrast-enhanced mri * radiotherapy for extracranial lesions is permitted * tyrosine kinase inhibitors (tki) are permitted in patients with progression of * intracranial metastases during previous tki therapy * patients have measurable or evaluable lesions based on the response evaluation criteria in solid tumors (recist) criteria * eastern cooperative oncology group (ecog) performance status 0-1 * normal function of organs and bone marrow within 14 days: total bilirubin 1.5 times or less the upper limits of normal (uln); ast and alt 1.5 times or less the uln; absolute neutrophil count≥ 500 cells/mm3; creatinine clearance rate(ccr) ≥45 ml/min; platelet count≥50,000 cells/mm3; international normalized ratio(inr) ≤1.5#prothrombin time (pt)≤ 1.5 × uln * informed-consent exclusion criteria: * small cell carcinoma of lung * intracranial metastases needed surgical decompression * patients with contraindications for mri * previous radiotherapy or excision for intracranial metastases * hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (new york class ii or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months * uncontrolled hypertension (systolic \> 150mmhg and/or diastolic \> 100mmhg) * major surgery within 28 days or minor surgery or needle biopsy within 48 hours * urine protein 3-4+, or 24h urine protein quantitative \>1g * severe uncontrolled disease * uncontrollable seizure or psychotic patients without self-control ability * women in pregnancy, lactation period * other not suitable conditions determined by the investigators

Keywords: mri-guided radiotherapy lung cancer brain metastasis
pediatric intubation among nursing

Conditions: Cardiac Arrest; Intubation, Endotracheal

Summary: the aim of this study was to compare time, success rates of video laryngoscope and direct laryngoscope for the emergency intubation with an immobilized cervical spine in a standardized pediatric manikin model.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * minimum 1 year of work experience in nursing exclusion criteria: * not meet the above criteria * wrist or low back diseases
improvement of migraine severity and frequency with migraineguard ™

Conditions: Migraine; Headache

Summary: numerous treatments have been recommended for the prevention of migraine. the purpose of this randomized double-blind placebo controlled trial was to assess the efficacy of migraineguard ™ supplement by herbacure natural containing a combination of coq10 , magnesium, riboflavin ,feverfew , skullcap and black pepper as prophylactic treatment for migraine.

our team will assess migraineguard ™ , a migraine prevention supplement marketed herbacure natural for individual suffering from multiple migraine attacks in one month . the purpose of this 7-months , randomized, double-blind, placebo controlled study is to evaluate the efficacy and safety of migraineguard ™ produced by herbacure natural , a canadian company based in vancouver , bc , in reducing migraine headache severity and frequency of attacks compared to placebo when used every day, as a preventative solution for migraine and to assess and monitor the safety of its usage for adverse effects. the primary end-point is the severity and the frequency reduction of migraine attacks. the secondary end-points will be the existence of adverse reaction.

Eligibility criteria:
inclusion criteria: * adult aged 18 to 65 years female and male * based on ihs criteria ,are diagnosed with migraine (criteria of the international classification of headaches disorders) * individuals with minimum of 3 severe to extreme migraine attacks during the last 3 months . * generally in good health exclusion criteria: * individuals taking any preventive treatment for migraine * excessive usage of painkillers * cancer \& head injury and trauma * any medical condition that may impact the validity of collected information * previous usage of botox within 6 months of study * last week usage of triptans

Keywords: migraine headache
effectiveness chronic kidney disease & therapeutic exercise

Conditions: Kidney Diseases; Exercise

Summary: the purpose of this study is to assess the effectiveness and safety of the therapeutic exercise effects in patients with chronic kidney disease. an randomized clinical trial is carried out. a total sample of 70 patients with chronic kidney disease is recruited and divided into a therapeutic exercise group and a control group. the kidney function (creatinine clearance as main outcome) is measured at baseline and 1 month after treatment start.


Eligibility criteria:
inclusion criteria: * patients with chronic kidney disease exclusion criteria: * cognitive impairment and non signed consent inform form
biomoleculars markers of sensitivity to pre- and post-operative chemotherapy of gastric and cardia adenocarcinomas: a pilot study

Conditions: Gastric and Cardia Adenocarcinomas

Summary: some subtypes of gastric and cardia tumors such as adenocarcinoma or gastric linitis with disseminated cells respond poorly to the pre-operative chemotherapy, and some of them do not respond to chemotherapy usually performed. doing chemotherapy in these patients could delay their surgical management. the completion of chemotherapy for these patients would be a bad prognosis factor according to recent data from the literature. therefore, the aim of this research is to find prognostic markers of sensitivity to chemotherapy usually performed. the investigators are going to use biopsies realized at diagnosis and select patients "good and bad" responders. primary purpose: to study cardia and gastric tumors, molecular markers sensitivity to pre- and post- perative chemotherapy protocols (eox protocol ... folfox) or chemoradiation secondary purposes: * to assess the impact of patients' lifestyle (via a questionnaire) on the response to chemotherapy * to study markers of cancer stem cells * to correlate clinical and molecular markers with patient survival and quality of life questionnaires * to characterize the expression levels (met, her2, fgfr2) and mutations (p53 ras) in frequently deregulated genes in gastric cancers. * to characterize the level of expression of predictive candidate markers (δnp73, tap73, hdac4, mir140, ezh2, cxcl12, cxcr4, cxcr7) found in the literature. * to correlate the abnormalities found in the with tumor stages (before and after chemotherapy) and with 5 years overall survival and progression-free patients


Eligibility criteria:
inclusion criteria: gastric adenocarcinoma (any location) or cardia adenocarcinoma * age\> 18 years * who index≤ 3 * subject having signed an informed consent exclusion criteria: * other cancers undergoing chemotherapy treatment * pregnant or breastfeeding * inability to understand information (understanding with difficulties ...)

Keywords: gastric cancer cardia cancer
cellular and humoral immunity in elderly after immunization with a japanese encephalitis vaccine

Conditions: Humoral and Cellular Immune Responses

Summary: the aim of this project is to investigate humoral and cellular immune responses before and after immunisation with the japanese encephalitis vaccine ixiaro in subjects above 60 years of age and 18-40 years old subjects.


Eligibility criteria:
inclusion criteria: * adults (18-40 years old) * adults (≥60 years), * both sexes * willingness to sign written informed consent form exclusion criteria: * age below 18 years or between 41-59 years old * status post japanese encephalitis, tick born encephalitis (tbe), dengue, yellow fever or west nile virus infection * previous immunization against yellow fever, japanese encephalitis (dengue or wnv) * current acute infection (body temperature above 37,9°c)
mechanistic interventions and neuroscience of dissociation

Conditions: Dissociation

Summary: the purpose of this study is to test the neurophysiological mechanisms of an intervention to reduce symptoms of dissociation in traumatized people. the intervention will be tested in dissociative traumatized people at two sites: emory university and university of pittsburgh. the researchers are interested in whether neural networks associated with attentional control and interoceptive awareness can be enhanced in this population. the researchers propose to evaluate whether different body-focused and non-body focused interventions can change these mechanisms.

people exposed to chronic trauma face devastating effects to the brain and body. chronically traumatized people become highly distressed when attending to emotional stimuli, which can lead to feelings of detachment from their bodies and environment. it is difficult to engage highly dissociative traumatized patients in trauma-focused treatment; however, these patients benefit from acquiring basic emotion regulation skills, including present-centeredness and body awareness. various practices that involve present-centeredness and body awareness (including mindfulness-based interventions) have been shown to demonstrate short-term and long-term improvement in cognition, emotion regulation and clinical symptoms in dissociative people with trauma exposure. in order to address this issue, the researchers will evaluate the effectiveness of interventions that engage present-centered awareness and/or body focus.

Eligibility criteria:
inclusion criteria: * experience of at least one diagnostic and statistical manual of mental disorders (dsm-5) criterion a trauma (assessed using the life events checklist) * a score of 7 or higher on the multiscale dissociation inventory (mdi) depersonalization subscale * willingness to participate in the study exclusion criteria: * actively psychotic and cognitively compromised individuals (assessed using the moderate-severe cognitive impairment screening tool (moca) will be excluded * moderate or more severe substance dependence (assessed with the mini) * persons with imminent risk of physical violence to self or others

Keywords: trauma ptsd mindfulness meditation neuroimaging mri
yoga for chronic low back pain and its mechanism of action (yoma)

Conditions: Chronic Low Back Pain

Summary: this is a study to better understand how a yoga intervention helps improve symptoms in people with chronic low back pain. this study will be a 12-week intervention of about 24 participants with chronic low back pain where all individuals will receive weekly yoga classes and instructions for home practice. the purpose of this study is to collect feasibility data and to conduct preliminary analyses in preparation for a larger planned nih study.


Eligibility criteria:
inclusion criteria: * chronic low back pain lasting \> 3 months * back pain that is rated at least 3 on a numeric pain rating scale that ranges from 0 to 10 (0-no pain, 10 worst pain imaginable). * english language fluency exclusion criteria: * bmi \> 40 * inability to provide informed consent * recent diagnosis of abdominal aneurism * recent diagnosis of metastatic cancer * recent diagnosis of discitis * recent diagnosis of disk disease * recent diagnosis of spinal stenosis * recent diagnosis of spondylolisthesis * recent diagnosis of infectious cause of back pain * recent diagnosis of fracture of vertebra * recent diagnosis of fibromyalgia * recent diagnosis of rheumatoid arthritis * recent diagnosis of ankylosing spondylitis * recent diagnosis of paralysis * pregnancy * prior or planned back surgery * blindness or severe vision problems * deafness or severe hearing problems * bipolar or manic depression and not taking medication * major depression * psychoses (major) * a substance abuse condition * dementia * unable to get up and down from the floor * involvement in a lawsuit related to back pain * lack of transportation * other disabling chronic conditions (e.g., disabling heart or lung disease, diabetic neuropathy, receiving treatment for hepatitis) * currently (within the past 3 months) using yoga classes for more than 15 minutes per week * inability to be contacted by phone or email * no computer access * schedule does not allow for participation in classes/home practice * planning to move out of town or take a long vacation during the period of the study
a multicenter phenotype-genotype analysis of dm1 patients in china

Conditions: Myotonic Dystrophy 1

Summary: myotonic dystrophy 1 (dm1) is an autosomal, dominantly inherited neuromuscular disorder characterized by skeletal muscle weakness, myotonia, cardiac conduction abnormalities, cataracts, and other abnormalities. this disease results from an expansion of a cytosine-thymine-guanine (ctg) trinucleotide repeat in the 3'-untranslated region of the dystrophia myotonica protein kinase (dmpk) gene on chromosome 19. currently, there is limited phenotype and genotype data available for dm1 patients with chinese han ethnicity. therefore, this study aims to fill this gap and provide complementary data.

this is a multicenter-based, prospective, observational study that primarily focuses on the diagnosis and progression of dm1 patients in china. the investigators collect patient data, including basic information, strength evaluations, genetic data, electromyography results, cognitive performance, and mris.

Eligibility criteria:
inclusion criteria: * age between 18-80 years * with enough cognitivie ability to understand the content and sign the informed consent form * with ctg repeats \>50 in dmpk gene, revealed by pcr test exclusion criteria: * patients with severe mental illness, or severe anxiety and depression * with comorbidities such as traumatic brain injury and cranial tumors * a history of alcoholism, psychotropic substance abuse, etc. * patients with severe medical conditions and unstable vital signs that cannot tolerate the tests. * female in pregnancy

Keywords: observational
pharmacokinetic assessment of standard half-life (shl) fviii, extended half-life (ehl) fviii, and efanesoctocog alfa (bivv001) in severe hemophilia a

Conditions: Hemophilia A

Summary: primary objective • to assess the half-life of bivv001, standard half-life (shl) rfviii and extended half-life (ehl) rfviii after a single intravenous (iv) injection secondary objectives * to characterize additional pharmacokinetic (pk) parameters of bivv001, shl rfviii and ehl rfviii after a single iv injection * to evaluate the safety and tolerability of a single iv injection of bivv001

this is a phase 1, single center, open-label, sequential treatment, 3-period fixed sequence study to assess pk profiles of bivv001, shl and ehl rfviii after a single iv injection in male, previously treated patients, 18-65 years of age, with severe hemophilia a (defined as \<1 iu/dl \[\<1%\] endogenous fviii). the expected duration of the study is up to approximately 67 days including * screening and washout up to 28 days, * advate® dosing, pk sampling, including washout: approximately 4 days, * adynovi® dosing and pk sampling, including washout: approximately 7 days, * bivv001 dosing and pk sampling: approximately 14 days, remainder of safety observation period: approximately 14 days.

Eligibility criteria:
inclusion criteria: * severe hemophilia a, defined as \<1 iu/dl (\<1%) endogenous fviii activity. * previous treatment for hemophilia a, defined as at least 150 days documented prior exposure to any recombinant and/or plasma-derived fviii and/or cryoprecipitate products at day 1. * platelet count ≥100,000 cells/µl at screening. * a participant known to be human immunodeficiency virus (hiv) antibody positive, either previously documented or identified from screening assessments, must have the following results prior to enrollment. (cd4 lymphocyte count \>200 cells/mm³ - viral load of \<400 copies/ml). exclusion criteria: * any concurrent clinically significant liver disease that, in the opinion of the investigator, would make the participant unsuitable for enrollment. this may include, but is not limited to cirrhosis, portal hypertension, and acute hepatitis. * serious active bacterial, fungal or viral infection (other than chronic hepatitis or hiv) present within 30 days of screening. * other known coagulation disorder(s) in addition to hemophilia a. * history of hypersensitivity or anaphylaxis associated with any fviii product. * history of a positive inhibitor test defined as ≥0.6 bu/ml, or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 bu/ml, or clinical signs or symptoms of decreased response to fviii administrations. family history of inhibitors will not exclude the participant. * positive inhibitor result, defined as ≥0.6 bu/ml at screening. * major surgery within 8 weeks of screening. * sensitivity to any of the study interventions, or components thereof, or drug or other allergy. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
skin oxygenation whilst wearing gradusox™ compression hosiery

Conditions: Effect of Compression Hosiery on the Local Tissue Oxygenation and Compare This Effect Against That Achieved by Standard Compression Hosiery

Summary: the primary objective is to evaluate the effect of gradusox™ compression hosiery on the local tissue oxygenation and compare this effect against that achieved by standard compression hosiery.

after being informed about the study, all participants giving written informed consent will be randomised by closed envelope randomisation to either a) first, gradusox on their right leg and sigvaris on their left leg, then gradusox on their left leg and sigvaris on their right leg, or b) first, gradusox on their left leg and sigvaris on their right leg, then gradusox on their right leg and sigvaris on their left leg. participants will attend the clinic and be fitted with their stockings. non-invasive probes will be taped to the skin above the inner ankle on both legs - these take measurements for so2, oxyhb and deoxyhb every second. measurements for these variables will be taken for 15 minutes whilst participants are not wearing stockings, as well as with stockings (worn in the order assigned to them). during these 15 minutes, participants will lie in supine for 5 minutes, then in sitting position for 5 minutes, then will return to supine for the last 5 minutes. between each stocking, participants will be asked to take a 10 minute walk and return to the recliner in supine to re-equilibrate for a further 15 minutes. the total time that measurements are taken for per participant is 50 minutes.

Eligibility criteria:
inclusion criteria * adults aged 18 and over. * have known previous venous insufficiency that has been treated. * have no known current contraindication to the wearing of graduated compression hosiery. * have an ankle brachial pressure index (abpi) between 0.8-1.2. * have no active ulceration. * are physically able to apply and remove hosiery kits safely. * have had successful surgery at the whiteley clinic and have had at least one follow-up to show no residual venous disease. exclusion criteria * under the age of 18. * have known arterial insufficiency (an abpi of below 0.8). * have active ulceration. * be physically unable to put stocking on their own legs. * have signs of recent lower limb trauma, active infection, ongoing untreated venous disease, significant ankle oedema. * unable to give informed consent. * pregnant. * fragile skin that may be damaged whilst trying to apply or remove compression stockings. * previous dvt or complicated varicose veins that were not able to be completely treated and left residual venous reflux disease.
an exploratory study of cluster of differentiation 38 (cd38) monoclonal antibody combined corticosteroid in acquired hemophilia a

Conditions: Acquired Hemophilia

Summary: to evaluate the time of response, sustained remission rate and relapse rate of cd38 monoclonal antibody (daratumumab) combined corticosteroid in the treatment of aha. to evaluate the safety of cd38 monoclonal antibody in the treatment of aha.

this is a prospective ,single-arm, multi-center controlled pilot trial of cd38 (daratumumab) monoclonal antibody combined corticosteroid in the treatment of aha patients. patients will receive daratumumab and corticosteroid treatment in this trial.

Eligibility criteria:
inclusion criteria: * patients must meet all enrollment criteria before they can be enrolled: diagnosed as aha; women are postmenopausal women or women of childbearing age with strict contraception; patients with good compliance exclusion criteria: * patients with any of the following items cannot be enrolled in this study: congenital hemophilia with inhibitor; pregnant and lactating women; who are positive for hepatitis b surface antigen, hepatitis c antibody, hiv antibody (ⅰ + ⅱ) and syphilis antibody; patients with poor compliance; who cannot use contraception during the trial; researchers believe that it is not appropriate for patients to participate in any other condition of this trial; four weeks before entering the group, the patients received immunosuppressive therapy and the inhibitor showed a progressive decreasing trend (the change was less than 50%). acquired von willebrand disease